Skip to content

    Saakshi Medtech

    SAAKSHI
    Capital Goods·28 Nov 2025
    Management Summary

    Saakshi Medtech reported a strong H1 FY26, with revenue growing 31% YoY to Rs. 58.31 crores and EBITDA improving to 18.71%. This growth was driven by a seven-fold increase in aerospace revenue and a 40% surge in the integrated control system segment. While net profit reached Rs. 6.63 crores, the company saw a decline in cash due to ongoing CAPEX and increased working capital, alongside higher debt for facility expansion.

    Highlights

    5
    • Revenue from operations increased by approximately 31% year-on-year, reaching Rs. 58.31 crores in H1 FY26.

    • EBITDA improved significantly to 18.71%, reflecting effective cost control and operational optimization.

    • The aerospace sector demonstrated exceptional growth, with revenue increasing nearly seven-fold to over Rs. 1 crore in H1 FY26 compared to H1 FY25.

    • The integrated control system segment experienced a 40% year-on-year revenue surge, contributing 57-58% of total revenue.

    • The company reported a net profit of Rs. 6.63 crores for the period, indicating stable operational performance.

    Concerns

    3
    • Cash and cash equivalents declined from Rs. 3.26 crores to Rs. 1.59 crores due to CAPEX and working capital requirements.

    • Inventory and receivables are noted to be 'a bit on higher side' compared to the previous year, requiring management attention.

    • Long-term borrowings have increased due to new term loans utilized for the construction of the new integrated facility.

    Key financials

    Single quarter

    06 metrics
    1. 01Revenue₹58.31 Cr+31%YoY
    2. 02EBITDA Margin18.7%
    3. 03Net Profit₹6.63 Cr
    4. 04Total Assets₹147.63 Cr
    5. 05ROE6.5%

    Segment breakdown

    • Integrated Control System₹9 Cr64.3%
    • Engineered Metal Assembly₹5 Cr35.7%
    Donut· Share of Revenue Increase (H1 FY26 vs H1 FY25)

    Order Book

    high confidence

    Total Value

    ₹ 230 crores

    as of 2025-09-30

    quantified

    Execution

    yet to be executed over the next 4 years

    "The company typically has 3-month visibility for most OEM long-term contracts, with quarterly order inflows. For the present quarter, approximately Rs. 50 crores of orders are to be executed."

    Source:
    Q&A

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    ₹15 crores

    mainly from the cash flows that the business will generate

    Debt

    Debt disclosed

    Liquidity

    Cash ₹1.59 crores

    Cash and cash equivalents declined from Rs. 3.26 crores to 1.59 crores due to CAPEX and working capital requirements.

    Guidance & targets

    7
    CategoryTargetPriority
    Revenue
    FY26 Revenue
    Rs. 140-150 crores
    Medium
    Revenue
    H2 FY26 Revenue Growth
    15%
    High
    Revenue
    Long-term Revenue Target
    Rs. 200 crore mark
    High
    Profitability
    FY27 EBITDA Margins
    similar margin space
    Medium
    Profitability
    Radiator Business Margins
    20% odd
    High
    Market Share
    Aerospace Contribution to Revenue
    20% odd
    Medium
    Asset Utilization
    Asset Turn
    three times
    High

    Phase 2 Construction Completion & Radiator Orders

    By Feb of next financial year (FY27)
    CurrentUnderway, production orders expected to kick in.
    TargetCompletion of Phase 2, commencement of production orders from radiator segment.

    Why it matters

    Crucial for unlocking new revenue streams and leveraging the new integrated facility, contributing to FY27 growth.

    by the Feb of this next financial year, as we committed that our phase 2 of construction gets completed, we see that the production orders from that segment will kick in.

    How to verify

    guidance_and_targets

    Risks & concerns

    3
    RiskSeverity

    Increased Inventory and Receivables

    Inventory and receivables are 'a bit on higher side' compared to the previous year, attributed to catering for increased revenue.Analyst acknowledged

    medium

    Increased Long-term Debt

    Long-term borrowings have increased due to new term loans dispersed for the construction of the new integrated facility.Analyst acknowledged

    medium

    Certification Delays for GE Vernova Orders

    Certifications for GE Vernova's wind turbines are not yet completed, delaying order flow for another six months.Management acknowledged

    medium

    Q&A highlights

    8

    “typically our H2 is better than the H1, as we see over the past couple of years and we don't see a reason why we should not be in a position to also follow the same trend. So, typically there is a close to around 15% growth, which we see between H1 and H2. We honestly feel that we are in line with doing similar set of numbers for the end of this financial year.”

    Provides management's outlook on H2 FY26 growth and confirms the FY26 revenue target, indicating consistency with past trends.

    asked by Brijesh Parekh

    2 min read6 chapters

    Detailed Narrative

    01

    Strategic Relocation and Operational Leverage

    Saakshi Medtech is nearing completion and imminent commissioning of its new 41,000 sq ft integrated manufacturing facility. This strategic relocation is anticipated to unlock significant operational leverage, improve throughput, and eliminate over Rs. 2 crores in annual rental costs by consolidating operations from legacy premises. The second phase of expansion, targeting high-volume panels and the aviation sector, is also on track for completion by March 2026.

    02

    Exceptional Growth in Aerospace Sector

    The aerospace sector demonstrated remarkable growth in H1 FY26, with revenue from a key existing customer increasing nearly seven-fold to over Rs. 1 crore, up from Rs. 0.14 crores in H1 FY25. This surge is attributed to enhanced quality processes and advanced traceability systems. The company is also actively engaging with two new Tier-1 aerospace customers, having successfully completed initial audits and bid processes, aiming to diversify its premium customer base.

    03

    Robust H1 FY26 Financial Performance

    For H1 FY26, Saakshi Medtech reported a strong financial performance with revenue from operations increasing by 31% year-on-year to Rs. 58.31 crores. EBITDA improved significantly to 18.71%, reflecting effective cost control and operational optimization. The company achieved a net profit of Rs. 6.63 crores for the period, with ROE at 6.54% and ROCE at 7.45%, indicating improved financial efficiency.

    04

    Segmental Performance and Drivers

    The integrated control system segment, primarily driven by a major automation OEM, experienced a 40% year-on-year revenue surge, contributing approximately 57-58% of the total revenue. The engineered metal assembly segment also showed strong performance, accounting for around 37% of total revenue, with an increase of Rs. 5 crores compared to H1 FY25, highlighting balanced growth across core verticals.

    05

    Capital Expenditure and Balance Sheet Dynamics

    The company invested Rs. 15 crores in CAPEX during H1 FY26, with Rs. 9.4 crores in CWIP, primarily for infrastructure build-out. An additional Rs. 5 crores CAPEX is planned for the final leg of the new facility's completion, which will be funded by internal cash flows. While cash and cash equivalents declined from Rs. 3.26 crores to Rs. 1.59 crores due to CAPEX and working capital, the debt-to-equity ratio remains conservative at 0.17, with increased long-term borrowings supporting facility construction.

    06

    Outlook and Strategic Growth Avenues

    Management expects H2 FY26 revenue to grow by approximately 15% over H1, aiming for a full-year FY26 revenue close to Rs. 140-150 crores. Looking ahead, the company targets crossing Rs. 200 crores in revenue within the next couple of years, driven by the radiator business (with expected 20% margins) and further expansion in the aerospace sector, which is projected to contribute around 20% of the revenue cycle. The company also aims for a 3x asset turn on its gross block of Rs. 150 crores.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.